Proventus

Making Life Fairer

 

Help-Line 01233 334 879

 

Working together to make a difference

Disease Modifying Drugs & Therapies

 

 

Find Us Here

You tube
Follow Provpeter on Twitter
You Tube
twitter

If you have experienced any adverse side effects from a medication or therapy - Report it

Cladribine - Mylinax®  

Oral cladribine is a proprietary oral tablet formulation of Cladribine that is being studied in an effort to demonstrate possible benefits as a treatment for patients with relapsing forms of MS. Cladribine is a purine nucleoside analogue that interferes with the behaviour and the proliferation of certain white blood cells, particularly lymphocytes, which are involved in the pathological process of MS.

 

A major trial of the oral drug Cladribine – results of which are published in the New England Journal of Medicine on 20 January 2010 – has shown that it significantly reduces relapse and deterioration of the disease, and goes a long way to eliminating the unpleasant side effects associated with existing therapies.

 

Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks. The benefits need to be weighed against the risks. [1] (ClinicalTrials.gov number, NCT00213135) [2]

 

Side effects may occur                                                                                                                                                                                                               

 

Adverse side effects may occur

 

 

Other Web Pages                                                                                                                                                                                                                         

1. nejm.org [abstract]

2 clinicaltrials.gov

 

Top of Page